The radiological and biomechanical assessment using cement augmented cannulated pedicle screw (Biomet^®, Omega 21^®) and the correlation of the cement volume to the pullout strength needed for each screw

Cadaveric vertebrae of different lumbar levels were used. Through cannulated pedicle screw a definite volume of cement was applicated. The bone volume occupied by cement was assessed by means of segmentation after Computer Tomography. Biomechanical Pullout tests and statistical correlation analysis were then performed

The maximum pullout strength was 1361 N and the minimum pullout strength was 172 N (SD 331 N). The maximum cement volume was 5,29 cm3 and the minimum 1,02 cm3 (SD 1,159). The maximum cement diameter was 26,6 cm and the minimum cement diameter was 20,7 cm (SD 1,744). There is statistically significant correlation between the pullout strength and the injected cement volume (p< 0,05).

The cannulated pedicle screw was used for a better fixation in the vertebral body. The cement augmentation with this technique is easier and seems to be safer than cement augmentation of non cannulated screws. Pullout strength of the cannulated screws correlates positively with the cement volume. It is though not influenced either by the total vertebral volume or by the ratio cement volume to vertebral volume or by the maximum diameter of the cement drough

The influence of the intravertebral length of vertebral screws on their pull out strength.

64 Cadaveric vertebrae of different lumbar levels were used. By means of Computer Tomography the length of the screw in the bone was assessed. The ratio screw length in bone to the longest possible screw in bone was built. Biomechanical Pullout tests and statistical correlation analysis were then performed

The maximum pullout strength was 1602 N and the minimum pullout strength was 96,4 N (SD 356,9 N). The maximum ratio of the inserted screw was 95,9% and the minimum was 58,8% (SD 0,7%). There is no statistically significant correlation between the ratio of the inserted screw and the pullout strength needed. Moreover, there is a statistically significant correlation between bone mass density and pullout strength (p< 0,05).

The fixation of pedicle screws is better in a non osteoporotic vertebral body. Pullout strength and bone mass density correlate significantly whereas there is no correlation between the insertion length of the screw and the pullout strength under the condition that the insertion ratio is greater than 58,8 %. Factors such as insertion angle of the screw need to be evaluated, and new techniques for pedicle screw fixation in osteoporotic vertebrae need to be developed

Dabigatran etexilate (Pradaxa^®) is an oral anticoagulant licensed in multiple countries, Europe and Canada, for the prevention of venous thromboembolic events (VTE) in patients undergoing total hip replacement surgery (THR) or total knee replacement surgery (TKR). The label recommendation for therapy initiation of dabigatran etexilate is a half dose given 1–4 hours after surgery. If this is not possible, then dabigatran etexilate should be started the day following surgery with the full dose. In the European pivotal Phase III clinical trials, this initial dosing was delayed until the day after surgery in 14% of the cases. This prompted a post hoc study to analyze if these patients received adequate thromboprophylaxis. Pooled efficacy data of major VTE events (composite of proximal DVT, symptomatic DVT, pulmonary embolism and VTE-related death) from the two European pivotal trials (RE-MODEL; Eriksson BI et al. J Thromb Haemost2007;5:2178–2185, and RENOVATE; Eriksson BI et al. Lancet2007;370:949–956) where analyzed. The group with delayed dosing was compared to the group that received therapy initiation on the day of surgery to determine if there was any significant effect on clinical outcome. The final decision on the timing of the administration of the first dose required sometimes clinical judgment, and in particular good haemostasis had to be present. Therefore, the bleeding rate and the timing of the first dose are confounded and an analysis of bleeding events was not performed. The major VTE rate in the group with delayed treatment initiation compared with the 1–4 hour post surgery treatment initiation group were 2.2% (95% CI: 0.1–4.4) vs. 3.0% (95% CI: 2.0–3.9) for 220 mg dabigatran etexilate, 8.3% (95% CI: 4.3–12.4) vs. 3.5% (95% CI 2.5–4.5) for 150 mg dabigatran etexilate, and 4.3% (95% CI 1.2–7.4) vs. 3.7% (95% CI 2.7–4.8) for 40 mg enoxaparin. As the confidence intervals overlap markedly, no statistically significant differences where found. In conclusion, no difference in the rates of major VTE and VTE related mortality was seen when the doses of dabigatran etexilate were postponed to the first postoperative day. These data need to be interpreted carefully due to the low number of patients in the delayed treatment group. As recommended in the current labelling of dabigatran etexilate, treatment should be initiated 1–4 hours post-surgery.

The oral direct thrombin inhibitor dabigatran etexilate (Pradaxa^®) was recently approved in Europe for the prevention of venous thromboembolism (VTE) in patients undergoing elective total knee or total hip replacement surgery. In the Phase III RE-MODEL (Eriksson BI et al. J Thromb Haemost2007; 5: 2178–2185) and RENOVATE (Eriksson BI et al. Lancet2007; 370: 949–956) clinical trials the safety and efficacy of 220 mg and 150 mg dabigatran etexilate once daily were studied. In both trials these doses were compared with 40 mg subcutaneous enoxaparin. A post hoc pooled analysis was performed in patients with moderate renal impairment (glomerular filtration rate ≥ 30 and < 50 ml/min) who participated in these two trials. The primary efficacy endpoint in both studies and the post hoc analysis was total VTE and all cause mortality; the key pre-specified secondary efficacy endpoint was major VTE and VTE-related mortality. Bleeding events (the primary safety endpoint) were blindly adjudicated and categorised as major bleeding events (MBE), which includes surgical site bleedings. A total of 1825 patients were treated with 220 mg dabigatran etexilate, 1866 with 150 mg dabigatran etexilate and 1848 with 40 mg enoxaparin. Of these, 337 patients had moderate renal impairment. 68% of these patients could be evaluated for the primary efficacy endpoint, 72% for the secondary efficacy endpoint, and all patients were included in the safety and bleeding analyses. The incidence of total VTE and all cause mortality was 17.7% (14/79), 23.5% (16/68) and 27.8% (25/90) in the 220 mg dabigatran etexilate, 150 mg dabigatran etexilate and enoxaparin groups, respectively. When the secondary efficacy endpoint was analysed a similar trend was seen, with a descriptive statistical significance for a lower event rate in the 220 mg group: 1.2% (1/83; p=0.04 vs enoxaparin using Fisher’s exact test), 4.3% (3/70) with 150 mg dabigatran etexilate; and 9.0% (8/89) in the enoxaparin group. MBE occurred in 6/113 patients (5.3%) in the 220 mg dabigatran etexilate-treated group, in none of the patients in the 150 mg dabigatran etexilate-treated group (0/96; p=0.04 vs enoxaparin using Fisher’s exact test), and in 6/128 patients (4.7%) receiving enoxaparin. Of note, 3/6 MBE in the 220 mg group started before oral dabigatran etexilate treatment was initiated. In conclusion, oral 150 mg dabigatran etexilate showed similar efficacy compared with subcutaneous enoxaparin in patients with moderate renal impairment undergoing hip or knee replacement surgery, with an apparently lower rate of major bleeding. As bleeding is a major concern, especially in this population, the 150 mg once daily dose of dabigatran etexilate is currently recommended by EMEA for this group.

Dabigatran etexilate (Pradaxa^®) is an oral direct thrombin inhibitor that was recently approved in Europe and Canada for the prevention of venous thromboembolism (VTE) in patients undergoing elective total knee replacement or total hip replacement surgery. Two pivotal clinical trials, RE-MODEL (Eriksson BI et al. J Thromb Haemost2007; 5: 2178–2185) and RENOVATE (Eriksson BI et al. Lancet2007; 370: 949–956), studied the efficacy and safety of 220 mg and 150 mg dabigatran etexilate once daily compared with 40 mg subcutaneous enoxaparin. A post hoc pooled analysis was performed in elderly patients (> 75 years) since renal function gradually declines with age. The primary efficacy endpoint was total VTE and all cause mortality and the secondary efficacy endpoint was major VTE and VTE-related mortality. The primary safety endpoint was major bleeding events (MBE), including those occurring at the surgical site. All bleeding events were blindly adjudicated. Of the patients treated with 220 mg dabigatran etexilate (n=1825), 150 mg dabigatran etexilate (n=1866) and enoxaparin (n=1848), 883 patients (16%) were over 75 years. 73% of these elderly patients were evaluable for the primary efficacy endpoint and 75% were evaluable for the secondary efficacy endpoint. All patients > 75 years were evaluable for safety outcomes, including bleeding. The incidence of total VTE and all cause mortality was 20.8% (44/212), 22.6% (49/217), and 27.2% (58/213), respectively, in the three groups. A similar trend was observed for major VTE and VTE-related mortality: 220 mg dabigatran etexilate, 1.9% (4/216, p=0.045 vs enoxaparin using Fisher’s exact test); 150 mg dabigatran etexilate, 4.5% (10/221); enoxaparin, 6.0% (13/218). MBE occurred in 11 of the 295 elderly patients receiving 220 mg dabigatran etexilate (3.7%), 4 of the 282 elderly patients receiving 150 mg dabigatran etexilate (1.4%) and in 9 of the 306 elderly patients taking enoxaparin (2.9%). Notably, 6/11 MBE in the dabigatran 220 mg group and 2/4 MBE in the 150 mg group started before the first dose of treatment. We conclude that in elderly patients (> 75 years) undergoing hip or knee replacement surgery, oral 150 mg dabigatran etexilate exhibited a numerically favourable bleeding profile with no difference in efficacy compared with 40 mg enoxaparin. Because safety, particularly bleeding, is of paramount importance in the elderly, the 150 mg once daily dose of dabigatran etexilate is currently recommended by EMEA for this group.

Dabigatran etexilate (Pradaxa^®) is an oral direct thrombin inhibitor that was recently approved in Europe and Canada for the prevention of venous thromboembolism (VTE) in patients undergoing total knee arthroplasty (TKA) or total hip arthroplasty (THA) surgery. In the phase III studies, concomitant administration of selective nonsteroidal anti-inflammatory drugs (NSAIDs with t½≤12 hours) and acetylsalicylic acid (ASA; < 160 mg/day) was allowed during treatment with dabigatran etexilate or enoxaparin. Due to the potential additional anticoagulant activity of these concomitant therapies a separate post hoc analysis was conducted to investigate the bleeding risk in these patients. We analysed the pooled study population (8,135 patients) from the three phase III trials in THA and TKA surgery (RE-MOBILIZE, RE-MODEL and RE-NOVATE) for major bleeding events (MBE). All MBE, which included surgical site bleeds, were assessed by an independent, expert adjudication committee. We report the rates of MBE and odds ratios (with 95% confidence intervals [CI]) for comparison of the subgroup concomitantly treated with NSAID (or ASA) versus the subgroup of patients without concomitant antithrombotically active medication. The overall rate of MBE (with and without NSAIDs and ASA) was 1.4% [CI 1.0–1.9], 1.1% [0.7–1.5] and 1.4% [1.0–2.0] with dabigatran etexilate 220 mg, 150 mg, and enoxaparin, respectively. Of the total population, 57.4% of patients received concomitant antithrombotic treatment: 54.1% received NSAID and 4.7% received ASA. The MBE rate in patients receiving dabigatran etexilate or enoxaparin plus NSAIDs was similar to the rate in patients taking only dabigatran etexilate or enoxaparin; 1.5% vs. 1.4% [OR 1.05; 0.55–2.01] for dabigatran etexilate 220 mg, 1.1% vs. 1.0% [OR 1.19; 0.55–2.55] for dabigatran etexilate 150 mg, and 1.6% vs. 1.2% [OR 1.32; 0.67–2.57] for enoxaparin. A similar pattern was seen in patients concomitantly receiving ASA; in this small group only a few patients with MBE were observed: 2 (1.6%) in the dabigatran etexilate 220 mg group, 2 (1.6%) in the 150 mg group, and 4 (3.0%) in the enoxaparin group. No relevant differences in risk for MBE were detected between treatments by co-medication subgroup or within treatment groups when comparing patients receiving dabigatran etexilate or enoxaparin only versus those concomitantly receiving NSAIDs or ASA. In conclusion, patients concomitantly receiving dabigatran etexilate and NSAIDs (with t½ ≤12 hours) or ASA (< 160 mg/day) have a similar risk of MBE to patients taking only dabigatran etexilate. These data support the use of dabigatran etexilate for the prevention of VTE in patients after THA or TKA, when concomitant use of NSAIDs or ASA (< 160 mg/day) is required.

Introduction: Patients who are prescribed bisphosphonates are still at risk to endure a fracture from weak and brittle bones. The question is what pharmacologic strategy should be taken to accelerate fracture healing when the patient is currently taking a bisphosphonate. Ibandronate, was tested in an osteoporotic rat model to determine how it modified the callus healing and resistance to torsion after a transverse fracture was produced in a femur.

Materials and Methods: 36 female rats were divided into 3 groups; ovariectomized (OVX) placebo control, non-OVX control and Ibandronate. Prior to the osteotomy, the Ibandronate treatment group was injected with the drug over 21 days healing. Each sample was scanned by the SCANCO uCT 80 to measure volume of the callus and quality of the trabeculae in the proximal femur. Instron testing recorded the modulus of rigidity and torque until failure. Yield point and toughness were also calculated.

Results: uCT images taken over the fracture gap showed that the Ibandronate rats had greater bone volume fraction of woven callus by ANOVA compared to control groups (p< 0.05). Significant in total callus volume for Ibandronate, were shown to be 32% larger than the non-OVX control group and 45% larger than the placebo group. Ibandronate also increased BMD of woven bone in the callus by 14%. Ibandronate showed the highest polar moment of inertia as well.

The torsion testing in Ibandronate had 51% greater toughness than placebo and 69% greater than the non-OVX group. Ibandronate increased trabecular number significantly over the placebo and was not significantly different from the non-OVX group. Trabecular separation was less in Ibandronate compared to the placebo group. Volume in the trabecular neck increased by 35% for the Ibandronate over the placebo.

Discussion: Ibandronate had an anabolic effect to produce more callus tissue at the fracture site, most likely by suppressing osteoclast remodelling activity. A large callus with more bone would increase fracture stability and reduce risk of non union. This is supported by a larger polar moment of inertia. Ibandronate had greater resistance to torsion, which could indicate better healing. However increased rigidity would not entirely benefit the healing unless the bone could handle load plastically. The toughness results showed that Ibandronate can absorb more energy than the control groups before refracturing. Continued treatment with this drug after a fracture could form a larger callus with greater mechanical toughness while also treating the disease of osteoporosis in other fracture risk sites of the body.

Introduction: It has recently been observed that around the site of a fracture bone loss of up to 10% can occur during the healing process. We hypothesized that trabecular bone around the site of a diaphyseal fracture is considerably diminished during the course of fracture healing and that this loss can be partly compensated by antiresorptive therapy.

Methods: 45 Sprague Dawley rats were randomly divided into 3 groups: Ovariectomy (OVX), sham operation (NON-OVX) and OVX with bisphosphonate (ibandonate) treatment (OVX+BIS). All animals received a standard closed mid diaphyseal fracture of the left femur fixed with an intramedullary pin. After 4 weeks of healing both femurs were excised and scanned with Micro CT to analyze bone architecture in the femoral head.

Results: There was significant osteopenia due to ovariectomy (p< 0.001). BV/TV was reduced by 30%. The fracture itself induced a similar osteopenia at the ipsilateral femur. In OVX animals the fracture induced osteopenia was potentiated by ovariectomy and amounted in a total bone deficit of 60% compared to healthy cancellous bone. Bisphosphonate treatment significantly reduced both the OVX and fracture induced osteopenia.

Discussion: A fracture leads to significant localized osteopenia at locations adjacent to the fracture site. Our findings suggest that the increased risk of secondary fractures after a first osteoporotic fracture might be related to the loss of trabecular bone caused by the fracture healing process. Therefore it is important to consider prevention measures for osteoporosis during the course of fracture healing in osteoporotic patients

BACKGROUND: Oral DVT prophylaxis not requiring monitoring is an advantage in orthopaedic patients. Dabigatran etexilate is an oral direct thrombin inhibitor undergoing evaluation for the prevention of venous thromboembolic events (VTE) following orthopaedic surgery.

METHODS: In a phase III, multicenter, non-inferiority, double-blind study, patients undergoing total knee replacement were randomized to 3 treatments. The patients received 8±2 days of oral dabigatran etexilate, 150 or 220 mg once daily starting with a half dose (i.e.75 or 110 mg) 1–4 hours after surgery, or subcutaneous enoxaparin 40 mg once daily starting 12 hours prior to surgery. The primary efficacy outcome was the composite of total VTE and all causes of mortality during the treatment period. All efficacy and safety outcome events were adjudicated by blinded independent committees.

RESULTS: Efficacy could be evaluated for 1541 (75%) treated and operated patients. Total VTE and death occurred in 40.5%, 36.4% and 37.7% of patients assigned to dabigatran etexilate 150 or 220mg once daily or enoxaparin, respectively. Proximal DVT and/ or PE occurred in 3.8%, 2.6% and 3.5% of patients receiving dabigatran 150 or 220mg or enoxaparin, respectively. Three deaths occurred during the treatment period, one in each of the treatment groups. Safety was evaluated for all 2076 patients receiving study treatment. The rate of major bleeding was 1.3%, 1.5% and 1.3% of patients receiving dabigatran 150 or 220mg or enoxaparin. Elevated LFTs (ALT > 3xULN) occurred in 3.7%, 2.8% and 4.0% of the patients treated with 150 and 220 mg dabigatran or enoxaparin during the study. A temporary rise in LFTs was observed during the follow-up period in 0.5% of the patients who had received dabigatran and in 0.4% of the patients who had received enoxaparin.

CONCLUSIONS: Non-inferiority for the primary efficacy endpoint was met for both doses of dabigatran etexilate compared to enoxaparin. There was no difference in bleeding rates between the treatment groups. Oral administration of dabigatran etexilate once daily, given early in the postoperative period, was effective and safe for the prevention of total VTE in patients undergoing total knee replacement surgery.

Chondrocyte sensitivity to strain depends on signal transduction pathways which include integrin-dependent increases in intracellular calcium. Human articular chondrocytes were cultured as monolayers in silicone dishes. After loading the cells with the calcium-fluorescent dye Fluo-3/AM the dishes were mounted in a 4-point bending apparatus and then fixed to a laser scanning confocal microscope. Biaxial substrate strain (15 000e) was applied to the silicone dish via a hand operated cam rotated at ~60 RPM (1 Hz) for 10 or for 50 cycles. Changes in intracellular calcium in single cells were determined by measuring the mean pixel values in the basal and stimulated images taken at different time points. The data reported for 50 cycle treatments represent 49 single cells of six independent cell isolations. The data for 10 cycle strain treatment are from a single experimental setup.

Increases in intracellular calcium were consistently observed in chondrocytes exposed to 15 000me for 50 cycles in a range from 1.3- to 4.0-fold with an average of 2.3-fold (SD=0.79). Few cells responded before 30 minutes but most of the responses occurred 30–60 minutes after strain. Consistent intracellular Ca++-increases were also seen after 10 strain cycles, however responses were detected within 5 minutes post-strain. The relative increase (2.7-fold ± 1.7) was similar in magnitude to 50 cycle responses.

Intracellular Ca++-fluxes in chondrocytes and other cells occur by at least two different mechanisms: through stretch-activated channels in the plasma membrane permit immediate Ca++-influx during strain application or by Ca++-efflux from intracellular compartments stimulated by slower acting second messengers. Our results suggest that the early response to 10 strain cycles is due to Ca++-influx via membrane channels while the later response to 50 cycles is due to Ca++-efflux from intracellular compartments, probably mediated by cytokines released in response to an initial Ca++-influx from the medium.